Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Trial Details

NCT ID

NCT07148128

Phase

PHASE1 / PHASE2

Sponsor

Auricula Biosciences Inc.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• WEF-001

Locations (sample)

• Dallas, Texas, United States|32.78306,-96.80667
• San Antonio, Texas, United States|29.42412,-98.49363
• Toronto, Ontario, Canada|43.70643,-79.39864
• Headington, Oxford, United Kingdom|51.75737,-1.21974

Key Eligibility Criteria

• Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovaria…
• Progressive disease following at least one line of standard of care therapy
• Measurable disease as defined by RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.